GSK3B and schizophrenia: Given that GSK3B is implicated in development of both Alzheimer’s disease and schizophrenia [9], [17]–[19], [22], this suggests that at least part of the relationship of these disorders with reduced intracranial volume may reflect the impact of GSK3B on brain development.